Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Study on recombinant BCG].

T Yamada1

  • 1Nagasaki University, Japan.

Kekkaku : [Tuberculosis]
|September 27, 2000
PubMed
Summary
This summary is machine-generated.

Recombinant BCG secreting Plasmodium yoelii antigen showed improved infection control compared to traditional methods. This enhanced BCG also demonstrated efficacy against Mycobacterium leprae and improved bladder cancer cell killing via IFN-gamma induction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[A case of staphylococcal enterocolitis caused by methicillin resistant Staphylococcus aureus].

Hinyokika kiyo. Acta urologica Japonica·1992
Same author

[Primary carcinoma in situ of the ureter: a case report].

Hinyokika kiyo. Acta urologica Japonica·1992
Same author

[Significance of normal oral flora, particularly group oral streptococci as defense mechanism against infection in healthy individuals (normal defense mechanism by oral Streptococcus group)].

Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases·1992
Same author

[Coronet status of digital radiography in chest medicine].

Nihon Kyobu Shikkan Gakkai zasshi·1992
Same author

Characterization of H2 histamine receptor: linkage to both adenylate cyclase and [Ca2+]i signaling systems.

The American journal of physiology·1992
Same author

Mapping of the gene encoding the beta-subunit of H+,K(+)-ATPase to human chromosome 13q34 by fluorescence in situ hybridization.

Genomics·1992
Same journal

[EXTERNAL QUALITY ASSESSMENT OF ANTI-TUBERCULOSIS DRUG SUSCEPTIBILITY TESTING FOR DIAGNOSING EXTENSIVELY DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS].

Kekkaku : [Tuberculosis]·2019
Same journal

[CLINICAL INVESTIGATION OF 6 CASES OF TUBERCULOUS SPONDYLITIS].

Kekkaku : [Tuberculosis]·2019
Same journal

[CONTROLLING TUBERCULOSIS IN FOREIGN-BORN PERSONS IN JAPAN].

Kekkaku : [Tuberculosis]·2019
Same journal

[EXPERIENCE OF USE OF NEW ANTI-TUBERCULOUS DRUG, DELAMANID IN MULTI- AND EXTENSIVELY DRUG RESISTANT TUBERCULOSIS CASES IN OUR HOSPITAL].

Kekkaku : [Tuberculosis]·2019
Same journal

[NONTUBERCULOUS MYCOBACTERIAL PULMONARY DISEASE].

Kekkaku : [Tuberculosis]·2019
Same journal

[MYCOBACTERIOSIS ASSOCIATED WITH ADMINISTRATION OF BIOLOGICS].

Kekkaku : [Tuberculosis]·2019
See all related articles

Area of Science:

  • Microbiology
  • Immunology
  • Vaccinology

Background:

  • Recombinant BCG offers a versatile platform for vaccine development and immunotherapy.
  • Studies have explored BCG's potential in delivering foreign antigens to elicit immune responses.
  • The use of BCG as a vector for parasitic and bacterial antigens is an active area of research.

Discussion:

  • Recombinant BCG secreting alpha antigen-fused merozoite surface protein 1 (MSP 1) demonstrated superior control of Plasmodium yoelii infections compared to conventional adjuvant-based approaches.
  • BCG engineered to overexpress antigen 85 complex A effectively managed Mycobacterium leprae infections.
  • The combination of BCG with interleukin-2 (IL-2) enhanced interferon-gamma (IFN-gamma) production, leading to more efficient killing of bladder cancer cells.

Key Insights:

Related Experiment Videos

  • Engineered BCG strains can elicit robust immune responses against diverse pathogens.
  • Recombinant BCG secreting specific antigens provides a promising strategy for infectious disease control.
  • BCG-based immunotherapy shows potential in cancer treatment by modulating the immune microenvironment.

Outlook:

  • Further research into optimizing antigen delivery and immune stimulation by recombinant BCG is warranted.
  • Clinical trials are needed to evaluate the safety and efficacy of these recombinant BCG candidates in humans.
  • Recombinant BCG holds promise for developing novel vaccines and immunotherapies for infectious diseases and cancer.